Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.

The PATHFINDER 2 study found that a blood-based multi-cancer early detection test achieved a cancer detection rate of 0.54% with high specificity and positive predictive value in adults aged 50 and older.

• Why it matters: Early detection of cancer can significantly improve survival rates, but many cancer types lack effective screening tools, creating a critical need for reliable blood-based tests to identify cancers early.
• What they did: The study enrolled over 35,000 participants and evaluated the test’s performance metrics—including detection rate, predictive values, and CSO accuracy—and assessed safety by tracking invasive procedures and adverse events over 12 months.
• The result: The test demonstrated strong performance with a 91.3% CSO prediction accuracy and minimal safety concerns, supporting its potential for broader clinical use pending further trials and long-term follow-up.